Transcript MRC Development and Disease

MRC Respiratory
Development and Disease
Consortium
Dr Matt Hind and Dr Charlotte Dean
National Heart and Lung Institute, Imperial
College and MRC Harwell
Background
Respiratory disease is common and increasing in
prevalence
WHO predicts COPD rise from 5th to 3rd commonest
cause of death by 2020
COPD costs NHS in excess of £1bn annually
Lung cancer common, highest mortality
Mismatch between funding available and prevalence
of disease
Few effective treatments for chronic respiratory
disease
Consortium members
National Consortium across UK (IC, UCL, Cambridge,
Southampton, Nottingham, Newcastle and Sheffield
(28 PIs)
International expertise in mouse lung phenotyping
and disease modelling
Strong link between bench and clinic
Translational pipeline
Mutant studies
Disease Modelling
Human tissue studies (primary cell culture, tissue
modelling and ex vivo models)
Link with existing NIHR funded Respiratory BRU and
BRC’s with mission of first into man studies
Strategic aims
To prioritize target genes identified from investigator
led research
Secondary phenotyping of selected mutants eg
asthma; flexivent lung function, immunological
profiling, epithelial barrier integrity
gene function from development through to adulthood
and the role in established disease models
develop high throughput phenotype screening (WBP)
Research Aims
models of bronchopulmonary dysplasia or prematurity
models of asthma
models of COPD/emphysema
models of lung cancer
models of acute lung injury
models of fibrosis
models of lung regeneration
Plan of action
Investigator led phenotyping tailored to research
interest but overlap between groups and outside
consortium
both airway and parenchymal specific cre drivers
use of conditional and inducable conditional tissue
(CCSP-cre, SPC-cre) specific and other suitable
drivers eg myeloid specific
To maintain MRC lung database for consortium
members to upload info
Delivery of strategic aims
Prority of initial genes where facilities (funding and
space) exists to take mice currently
Selection of candidate genes based on consensus
and equity across disease areas
Provision of mutants
Feedback of metrics
Contact
•
[email protected]
•
[email protected]